Nascent Biotech Announces Initial Dosing Underway in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

SAN DIEGO, CA, USA I March 31, 2021 I Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech," "Nascent," or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that patients have been enrolled and initial dosing has begun in the Company's landmark Phase I trial to evaluate Pritumumab ("PTB") as a treatment option for Brain Cancer, including Malignant Primary Brain Tumors and adult Brain Metastases.

Patient enrollment remains open, and the trial continues to recruit new patients for participation. Those interested may review trial requirements HERE.

"Dosing human cancer patients in our Phase 1 clinical trial is a key milestone on the path toward determining the safety profile of Pritumumab under clinical conditions," noted Nascent CEO Sean Carrick. "This study will also provide fresh insight into PTB's efficacy on primary brain tumors."

PTB is a natural human antibody that works by binding to cell surface Vimentin (also referred to as ectodomain vimentin, or EDV), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy that, unlike chemotherapy, targets only cancer cells without damaging healthy ones. Because of this dynamic, the current clinical study may have implications for future research on PTB as a treatment option for a broad range of more common cancers, including breast, colon, and lung.

For more information on the research studies and clinical trials, visit www.clinicaltrials.gov.

About Nascent Biotech

Nascent Biotech, Inc. (OTCQB:NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping millions of people worldwide. Its products are not yet commercially available. The Company's lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that is being studied in Phase I clinical trials for the treatment of Brain Cancer. Development for PTB as a treatment for COVID-19 has been initiated.

For further information, please visit our website www.nascentbiotech.com.

SOURCE: Nascent Biotech

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top